In addition, the Kras; Tgfbr2flox; Cre pancreatic cancer model (see Table 1) has been used to assess the efficacy of the EGFR (epidermal growth factor receptor) inhibitor erlotinib, as well as the effect of cancer-associated fibroblast depletion. This evidence concerns the gene KRAS and pancreatic neoplasm.